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Abstract
The Saguenay–Lac-Saint-Jean (SLSJ) region is located in northeastern Quebec and is known for its unique demographic
history and founder effect. As founder populations are enriched with population-speciﬁc variants, we characterized the
variants distribution in SLSJ and compared it with four European populations (Finnish, Sweden, United Kingdom and
France), of which the Finnish population is another founder population. Targeted sequencing of the coding and non-coding
immune regulatory regions of the SLSJ asthma familial cohort and the four European populations were performed. Rare and
low-frequency coding and non-coding regulatory variants identiﬁed in the SLSJ population were then investigated for
variant- and gene-level associations with asthma and allergy-related traits (eosinophil percentage, immunoglobulin (Ig) E
levels and lung function). Our data showed that (1) rare or deleterious variants were not enriched in the two founder
populations as compared with the three non-founder European populations; (2) a larger proportion of founder population-
speciﬁc variants occurred with higher frequencies; and (3) low-frequency variants appeared to be more deleterious.
Furthermore, a rare variant, rs1386931, located in the 3ʹ-UTR of CXCR6 and intron of FYCO1 was found to be associated
with eosinophil percentage. Gene-based analyses identiﬁed NRP2, MRPL44 and SERPINE2 to be associated with various
asthma and allergy-related traits. Our study demonstrated the usefulness of using a founder population to identify new genes
associated with asthma and allergy-related traits; thus better understand the genes and pathways implicated in
pathophysiology.
Introduction
The Saguenay–Lac-Saint-Jean (SLSJ) region is located in
northeastern Quebec and is known for its unique demo-
graphic history and founder effect, characterized by several
population bottlenecks followed by rapid expansion [1].
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Founder populations, like SLSJ, are usually less diverse at
the environmental and genetic levels [2], and harbor larger
identical DNA segment than outbred populations [3, 4]. An
advantage of studying founder populations is the possibility
to investigate variants, which occurred in higher frequencies
as compared with the general population, due to either
genetic drift or weaker selection against deleterious alleles
[5–8]. These effects can lead to overcome selection dis-
advantage and allow alleles to reach higher frequencies in
founder populations [9–12] such as the French-Canadian
[13] and Finnish populations [14]. These characteristics
make founder populations well suited to study the impact of
rare and low-frequency variants in complex traits, such as
asthma [11, 15, 16]. Recent studies showed the smaller but
important contribution of rare and low-frequency variants in
the genetic basis of complex traits [17, 18]. Despite the
major contribution of common variants, investigations of
rare and low-frequency variants in founder populations
would provide additional and insightful information about
the underlying biological mechanism of traits development.
Rare and low-frequency variants have been previously
studied to better understand the genetic basis of complex
traits such as asthma and allergic diseases [19–21].
Although these variants do not explain a large part of the
missing heritability they contribute nevertheless [19]. Rare
variants exploration identiﬁed previously associated genes
(ex: GSDMB [13], IL33 [15]) and new ones (ex: GRASP
[13]), highlighting the importance of studying their role in
the context of asthma and allergy-related traits.
In this study, we set out to identify new variants and
genes associated with various traits related to asthma and
allergy in hope to better understand the biological
mechanisms and pathways of these diseases. We aimed to
take an advantage of the well-characterized SLSJ cohort and
its availabilities of comprehensive phenotypes related to
asthma and allergy [1]. Our ﬁrst objective is to characterize
the variants distribution in the SLSJ founder population and
to compare it with four European populations (i.e., Finland
(FINN), Sweden (SWE), United Kingdom (UK) and France
(FR)). Of the four populations, the Finnish is another
founder population. As SLSJ is part of the French-Canadian
population, we wanted to follow-up on previous results and
see if we could observe the same enrichment of deleterious
variants in this population [13]. Our second objective is to
explore the functional consequences of identiﬁed rare
and low-frequency variants and their respective genes
in asthma and allergy-related traits in the SLSJ asthma
familial cohort [1]. Given that asthma and allergies are
characterized by multiple subphenotypes and endotypes, we
selected the quantitative traits related to both the immuno-
logical and clinical aspects for investigations: serum
immunoglobulin (Ig) E levels, eosinophil percentage and
lung function.
Materials and methods
Samples
We sequenced samples from 149 parent–child trios
(447 samples) from the SLSJ asthma familial cohort [1]. For
the characterization of variants distribution, of the
447 samples, 93 non-related parents were selected and
paired by mean coverage to avoid bias with 93 non-related
samples from each of the four study populations (FINN, FR,
SWE and UK) for a total of 465 samples. All studies
received ethic approbations from their respective ethic
committees.
To analyze the impact of rare variants on the phenotypes
of lung function (i.e., forced vital capacity (FVC), forced
expiratory volume in 1 s (FEV1) and Tiffeneau–Pinelli
index (FEV1/FVC)), serum IgE levels and eosinophil per-
centage, the sequenced data from the 149 sequenced trios
were used to infer and impute genotypes for the rest of the
cohort (1214 individuals from 254 families [1]; see Infer-
ence and imputation section; see Table 1 for Clinical
description and for Recruitment details). Lung function,
serum IgE levels and differential white blood cell counts of
the SLSJ cohort have been measured and published pre-
viously [1]. The study was approved by the Centre Intégré
Universitaire de Santé et de Services Sociaux du SLSJ
ethics committee. All subjects gave informed consent.
Capture and sequencing
Samples from the 149 trios from the SLSJ asthma familial
cohort and 93 non-related individuals from each of the four
European populations were all sequenced using a custom
capture panel developed by our group [22], followed by
next-generation sequencing. This custom capture panel
covers around 3% of the genome, including coding and
non-coding immune regulatory regions [22] (see Morin
et al. [22] for details about panel description, capture and
sequencing) because most of the variants associated with
complex traits are located in the non-coding region of the
genome [23]. This approach allowed us to assess the
impacts of rare and low-frequency variants in a cost-
effective manner. Moreover, the use of next-generation
sequencing was better suited in this context compared with
genotyping chips or linkage analysis due to the small effect
size and low-frequency of the variants we explored, as well
as the low heritability of the traits [24]. To remove any
potentially related individuals in the paired 465 subjects
(93 subjects from each of the ﬁve populations), we per-
formed an identity-by-descent estimation using the method
of moments [25] and a principal component analysis using
the SNPRelate R package [26] (Supplementary Figure 1A).
We also used heterozygous/homozygous proportion to
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identify and remove outliers and their paired samples
(Supplementary Figure 1B, C and D). A total of 380 sam-
ples (76 samples per population) were analyzed for variants
characterization at the end. Four hundred forty samples
from the SLSJ trios were kept for the second part of the
study.
Variant calling and ﬁltering
We aligned reads to the Genome Reference Consortium
Human genome build 37 (GRCh37) using bwa 0.7.6a and
we called variants using HaplotypeCaller v3.2 (GATK). We
performed merge calling for all samples in the ﬁve
populations and the 149 trios independently. Variants
included in both sample sets met these criteria: (1) inclu-
ded within the targeted regions, (2) biallelic sites, (3) dp >
10× and gq > 35 in at least 90% of the samples. We
removed the human leukocyte antigen region as it will be
analyzed independently. We compared the sequenced data
with genotyped data obtained for the 149 trios (447 indi-
viduals; see Genotyping section) as a quality control using
heterozygous and biallelic variants that were both in cap-
tured regions and on the genotyping chip. Seven samples
were removed due to a concordance of <95%. We also used
the comparison between sequenced and genotyped data to
set our ﬁltering cut-off to read depth (dp) > 10 × ,
Table 1 Clinical description of
the SLSJ asthma familial cohort
All samples
(n= 1214)
All trios
(n= 447)
Probandsa (n=
149)
Parents (n
= 298)
Siblings (n
= 110)
General characteristics
M:F ratio 1 :1.2 1:1.1 1:1.3 1:1.0 1 :1.2
Age, mean (range)b 38 (2–96) 36 (3–75) 18 (3–45) 45 (27–75) 14 (2–44)
Age of onset, mean (range)b 16 (0–75) 14 (0–64) 7 (0–37) 24 (0–64) 6 (0–44)
Smoking status, % (never
smoker; former smoker;
current smoker)c
54; 28; 18 51; 27; 22 82; 6; 12 36; 37; 27 82; 7; 11
Clinical descriptive data
FEV1, L (SD)
d 2.93 (0.82) 2.99 (0.76) 2.93 (0.80) 3.01 (0.74) 2.93 (0.88)
FVC, L (SD)e 3.73 (1.02) 3.82 (0.94) 3.71 (1.04) 3.87 (0.88) 3.52 (1.10)
FEV1/FVC, % (SD)
f 94.0 (9.0) 72.5 (22.4) 70.8 (29.6) 72.6 (21.2) 77.7 (21.1)
Serum IgE (SD)g 471 (1564) 432 (1406) 806 (2309) 251 (501) 276 (404)
Asthma, n (%)h 592 (49) 264 (59) 149 (100) 116 (36) 52 (47)
Allergy, n (%)i 677 (57) 287 (64) 121 (82) 170 (57) 73 (68)
With asthma, n (%) 433 (36) 206 (46) 121 (82) 90 (30) 37 (35)
Eosinophilsj
Count in 1e-9/L (SD) 0.24 (0.22) 0.25 (0.23) 0.32 (0.34) 0.21 (0.15) 0.26 (0.26)
Percentage (SD) 3.6 (2.8) 3.7 (2.8) 4.4 (3.3) 3.3 (2.4) 4.0 (3.4)
aProbands are the ﬁrst family member recruited in the cohort
bMean and median age calculated for 1212 subjects, 447 trios members, 149 probands, 298 parents and
110 siblings
cSmoking status was available for 1194 subjects, 444 trios members, 148 probands, 296 parents and
107 siblings. Ex-smokers are deﬁned as subject who stopped smoking since over 1 year
dThe mean forced expiratory volume in 1 s (FEV1) is measured in L in 925 subjects, 429 trios members, 141
probands, 287 parents and 94 siblings
eThe mean forced vital capacity (FVC) is measured in L in 908 subjects, 414 trios members, 134 probands,
279 parents and 92 siblings
fThe mean FEV1 (L)/FVC (L) ratio is calculated in % for 907 subjects, 414 trios members, 134 probands,
279 parents and 93 siblings
gThe geometric mean of immunoglobulin (Ig) E serum concentration is calculated for 996 subjects, 408 trios
members, 142 probands, 292 parents and 99 siblings
hPresent or past documented clinical history of asthma. Asthma phenotype is available for 1207 subjects, 447
trio members, 149 probands, 298 parents and 110 siblings
iAllergy is deﬁned as one positive skin prick testing (wheal diameter ≥ 3 mm at 10 min). The allergy
phenotype is available for 1193 subjects, 445 trio members, 147 probands, 296 parents and 106 siblings
jCell type proﬁles are available for 967 subjects, 418 trios members, 137 probands, 283 parents and
98 siblings
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genotyping quality (gq) > 35; an accuracy and a sensitivity
of > 95% were observed. We assessed Mendelian errors
using VCFtools [27] and a parent/proband pair was exclu-
ded due to high error rate. Mendelian errors in the
remaining samples were replaced by missing values.
Sequences were inferred and imputed from the sequenced
trios samples for the rest of the cohort (see Inference and
imputation sections). Functional annotation was performed
using SNPeff [28] and selectively constrained variants were
identiﬁed with the Genomic Evolutionary Rate Proﬁling
(GERP++ score) [29].
Genotyping
DNA extraction, genotyping (Illumina 610K Quad Array)
and variant ﬁltering of the 1214 individuals from the SLSJ
asthma familial cohort have been described previously [1,
30]. These samples include the 149 trios sequenced. Gen-
otyping data were used for quality cut-offs assessment,
inference and imputation of the sequence for the entire
cohort.
Inference and imputation
Genotype phasing was performed using SHAPEIT v2 and
duoHMM [31–33] to consider familial structures. Pre-
phasing was done using the trios (440 samples) using
merged sequencing and genotyping data, as well as on the
whole cohort using only genotyping data (1214 samples).
We inferred the sequence in the non-sequenced siblings
who were part of the same families as the trios. Chromo-
somes were separated by breakpoints that were identiﬁed
using duoHMM and NUCFAMTOOLS [34]. We were able
to reassemble the sequence in the siblings using informative
markers (heterozygous in one parent and homozygous in the
other) and we inferred on average 98.72% (96.89–99.33%)
of the sequence at an accuracy of 99.67% (99.39–99.86%).
We used the parental haplotypes (294 samples) as the
reference panel to reduce the number of duplicated haplo-
types and we imputed the sequence using IMPUTE2 [35] in
the whole cohort. Missing genotypes from the inference
were added using the imputed data. A total of 112,154
variants were imputed with a mean accuracy of 99.70%
(98.55–99.98%) and retained variants with imputation
quality of > 0.8 for a total of 112,083 variants. The impu-
tation accuracy was measured by comparing imputed pro-
bands to their sequenced data.
DNA methylation
We measured DNA methylation levels on a subset of
individuals from the SLSJ asthma cohort using whole blood
(167 samples) and isolated eosinophils from blood
(24 samples). Eosinophil cells isolation was performed as
described in Ferland et al. [36] and DNA extraction and
sodium bisulﬁte conversion were described in Liang et al.
[37]. Methylation levels were assessed using the Inﬁnium
HumanMethylation450 BeadChip array (Illumina, San
Diego, CA, USA). Normalization steps were described in
Morin et al. [38].
Statistical analyses
To assess variants distribution differences across the ﬁve
populations, the variant proportions or ratios were com-
pared using a chi-square test combined with Cramer’s V ( >
0.15 for 4 degrees of freedom) and an analysis of variance
(ANOVA) followed by Tukey's test to assess the differ-
ences of per sample distribution. p-Values reported for the
post hoc tests are adjusted for false discovery rate (chi-
square) or with Bonferroni correction (ANOVA).
We performed single-variant analyses on low-frequency
variants (0.01 < minor allele frequency (MAF) < 0.05) and
which were not common in the UK10K [39] or 1000
Genomes Project (1KGP) [40] for a total of 15,294 variants
(signiﬁcance threshold set to p < 3.3e–6). For the gene-
based test, we combined rare and low-frequency variants
per gene, including its surrounding 20 kb (including only
immune DNase I Hypersensitivity Sites (DHSs)) and only
included gene regions that had at least two variants for a
total of 14,646 (signiﬁcance threshold set to p < 3.4e–6 or
false discovery rate 5%).
We explored variants associated with the ﬁve investi-
gated phenotypes using EPACTS software (Efﬁcient and
Parallelizable Association Container Toolbox: http://
genome.sph.umich.edu/wiki/EPACTS). We performed a
mixed model association called EMMAX (Efﬁcient Mixed
Model Association eXpedited) that accounts for sample
structure (population structure and relatedness (kinship
coefﬁcient)). EMMAX supports single-variant association
tests and different burden tests (combined multivariate and
collapsing (CMC) [41] and Sequence kernel association test
(SKAT) [42] methods). The two burden tests were used
because of their different assumptions: CMC performs a
multivariate test on the variant counts in each gene region
[41], whereas SKAT combines the score of each variant in
the gene regions assuming their independence, thus allow-
ing them to go in different directions of effect [42]. Sex and
age were used as covariates, as well as height for lung
function assessment.
To determine if DNA methylation levels at genes asso-
ciated with asthma-related traits were associated with serum
levels, FEV1/FVC and asthma using whole blood
(167 samples) and blood isolated eosinophils (24 samples),
we applied a robust linear regression model including age
and sex as covariates, as well as cell type composition for
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whole blood. To assess if results were obtained by chance,
we performed 1000 permutations and determined if we get
the same number of CpGs with p < 0.05.
Data are available through EGA (https://ega-archive.org/)
for the SLSJ cohort (DAC: EGAC00001000901, Study:
EGAS00001003103) and for the other cohorts (DAC:
EGAC00001000409, Study: EGAS00001001564).
Results
Founder populations are enriched with population-
speciﬁc low-frequency variants
For the ﬁrst objective of characterizing variants distribution,
after removal of related individuals and outliers 76 samples
from the SLSJ cohort were paired with 76 samples from
each of the four other European populations (a total of 380
individuals). All ﬁve populations had a mean coverage of
28 × (18–52 × ) (Table 2). A total of 192,227 variants
(178,613 single-nucleotide variants (SNVs) and 13,614
indels) were called according to the aforementioned criteria
and summarized in Table 2. Given the small number of
samples being analyzed in this study, the rare variant
spectrum only includes singletons, which are rare variants
seen only one time. We observed a smaller number of
variants in both founder populations (total number of var-
iants: 111,669 (SLSJ), 108,485 (FINN), 120,473 (FR),
114,468 (SWE) and 116,937 (UK); Table 2) and was
reﬂected in the mean number of singletons per sample for
each population (Supplementary Table 1 and Supplemen-
tary Figure 2). A smaller proportion of singletons was
observed in the SLSJ (21.6%) and FINN (19.4%) popula-
tions compared with other populations (28%, 24% and 25%
for FR, SWE and UK respectively; Fig. 1a). Similar pro-
portions of low-frequency variants were observed across
each population (Fig. 1a). We observed a higher number of
low-frequency variants in the founder populations when the
mean number of variants per sample were compared with
the non-founder populations (ANOVA p < 2e–16; Fig. 1b).
For population-speciﬁc variants, which were only observed
in one population, higher proportions of low-frequency
variants were found in the SLSJ and FINN populations (chi-
square p < 2e–16, Fig. 1c) and higher mean numbers per
sample per population than the non-founder populations
(ANOVA p < 2e–16, Fig. 1d) compared with the smaller
proportion observed previously in public databases (chi-
square p < 2e–16; Supplementary Figure 3B). For rare
population-speciﬁc variants, we observed smaller propor-
tion in SLSJ and FINN than the non-founder populations
(chi-square p < 2e–16, Fig. 1c). For functional variants in
the SLSJ and Finnish founder populations, although not
signiﬁcant, we observed a larger proportion of nonsynon-
ymous, loss-of-function (LoF) and GERP++ > 4 low-
frequency variants (Supplementary Figures 4 and 5 and
Supplementary Tables 2 and 3), as well as a higher non-
synonymous/synonymous ratio trend and GERP++ > 4/
GERP++ < 2 in the low-frequency variants of the founder
populations compared with the others (Supplementary
Figure 6A and 7A). The trend was signiﬁcant when looking
at the mean ratios of variants per sample for each population
(ANOVA p= 3.72e–10 and p= 1.68e–9; Supplementary
Figure 6C and 7C). We also looked at the enrichment of
deleterious variants in the founder populations as compared
with the non-founder populations (Supplementary Fig-
ure 8). SLSJ has signiﬁcant excess of nonsynonymous low-
frequency variants as compared with FR and UK (chi-
square p= 8.3e–3 and p= 0.019; respectively, Supple-
mentary Figure 8A) and excess low-frequency GERP++ >
4 variants than FR and UK (chi-square p= 2.9e–3 and p=
0.048; respectively, Supplementary Figure 8C). Similar
patterns were observed for FINN; FINN has excess
low-frequency nonsynonymous variants than FR (chi-
square p= 0.048, Supplementary Figure 8B) and excess
low-frequency GERP++ > 4 variants than FR and UK (chi-
square p= 5.6e–4 and p= 0.014, respectively; Supple-
mentary Figure 8D). Similar patterns were observed for
population-speciﬁc variants (Supplementary Figure 9). No
difference was observed for the average GERP++ score per
sample distribution among populations (Supplementary
Table 2 Overall description of
variants included in the analyses
All SLSJ FINN FR SWE UK
Mean coverage 28.83 28.88 28.86 28.79 28.81 28.82
Ts/Tv 2.24 2.25 2.25 2.24 2.24 2.25
Total SNVs 178,613 103,889 100,696 112,047 106,375 108,511
Total indels 13,614 7780 7789 8426 8093 8426
Total singletona 420 371 377 425 354 372
SLSJ Saguenay–Lac-Saint-Jean, FINN Finland, FR France, SWE Sweden, UK United Kingdom, Ts/Tv
transition to transversion ratio, Indels insertions and deletions
aSingletons in the column entitled “All” corresponds to singletons across populations. The other columns
correspond to singletons within each population. Each population comprise 76 samples for a total of
380 samples
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Figure 10). However, greater average GERP++ scores in
the low-frequency variants were observed in SLSJ and
FINN as compared with FR and the UK (ANOVA p=
1.8e–7, Supplementary Figure 11A). Overall, we observed a
higher proportion of population-speciﬁc variants reaching
higher frequencies in the founder populations. We also
observed a tendency of enrichment for more deleterious
variants in the founder population, especially in the low-
frequency spectrum.
Low-frequency variant located in CXCR6/FYCO1 is
associated with eosinophil percentage in the SLSJ
founder population
We assessed the individual effect of the coding and non-
coding low-frequency (0.01 <MAF < 0.05) that were not
common in the UK10K [39] or 1KGP [40]. A total of
15,294 SNVs (Bonferroni threshold: p < 3.26e–6) were
analyzed for association with ﬁve asthma-related traits in
Fig. 1 Distribution of variants across founder populations compared
with three other European populations. a Proportion of common
(MAF > 0.05), low-frequency (0.01 <MAF < 0.05) and rare (single-
tons) (MAF < 0.01) variants in each population; b Low-frequency
variants distribution per sample, ANOVA p < 2e–16 and Tukey p <
1e–6; c Proportion of population-speciﬁc variants, common (MAF >
0.05), low-frequency (0.01 <MAF < 0.05) and rare (singletons; MAF
< 0.01), chi-square p < 2e–16 and Cramer’s V= 0.24 for both low-
frequency and rare variants and; d Population-speciﬁc variants dis-
tribution (not including singletons), ANOVA p < 2e–16 and Tukey
p < 1e–3. Population-speciﬁc variants are deﬁned as variants observed
in only one of the ﬁve populations but are not necessarily singletons.
To assess signiﬁcance, chi-square test (p < 0.05) and Cramer’s V ( >
0.15) were performed for a and c and ANOVA followed by Tukey
were performed for b and d. a= signiﬁcantly different from FINN, b
= signiﬁcantly different from SLSJ, c= signiﬁcantly different from
FINN and SLSJ. In c, SWE is also signiﬁcantly different from UK and
FR. SLSJ Saguenay–Lac-Saint-Jean, FINN Finland, FR France, SWE
Sweden, UK United Kingdom
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the SLSJ cohort. We observed a signiﬁcant association (p <
3.26e–6) with eosinophil percentage for SNV rs1386931:C >
T (p= 1.77e–6, effect size= 1.534), located in the 3ʹ-UTR of
CXCR6 and in the intron of the FYCO1 genes (Table 3 and
Fig. 2c). We also observed another SNV reaching suggestive
signiﬁcance (p < 1e–5) with serum IgE levels and it is located
in the intron of the NRP2 gene (rs849558:T > C, p= 4.79e–6,
effect size=−1.243; Table 3 and Fig. 2a). No variants were
identiﬁed to be associated with lung function. Both SNVs
were also found in 1KGP and UK10K. The SNV associated
with eosinophil percentage (rs1386931:C > T) has a higher
MAF in SLSJ (0.043) compared with the one observed in
1KGP (0.021) and UK10K (0.019). The other variant
(rs849558:T > C) had slightly higher frequency in SLSJ
(0.019) compared with UK10K (0.011).
NRP2 and MRPL44 are associated with serum IgE
levels and eosinophil percentage in the SLSJ cohort,
respectively
For the gene-based test, we combined rare and low-
frequency variants per gene, including its surrounding
20 kb (including only immune DHSs) and only included
gene regions that had at least two variants for a total of
14,646 genes (p < 3.4e–6 or FDR 5%). Two genes were
signiﬁcantly associated with serum IgE levels (NRP2, p=
3.16e–6; Fig. 3a and Table 4) and eosinophil percentage
(MRPL44; p= 2.97e–6; Fig. 3c and Table 4). One SNV
lead each association: a rare one for MRPL44 (rs76568361:
T > G) and a low-frequency one for NRP2 (rs849558:T > C;
Table 4). The latter almost reached signiﬁcance in the
single-variant association test (p= 4.79e–6, Table 3).
Moreover, we identiﬁed four marginally associated genes
(p < 1e–5, Supplementary Table 4). SHMT1 and SMCR8
were marginally associated with eosinophil percentage (p=
2.97e–6 and p= 6.21e–6; Fig. 3c) with the rare non-
synonymous variant rs79875842:A > G being the lead SNV
for both genes (Supplementary Table 4); CCDC126 and
CLK2P were marginally associated with FEV1/FVC (p=
4.62e–6; Supplementary Figure 12A) with rare nonsynon-
ymous variants (rs73077128:G > A and rs146336907:C >
T) for the pseudogene CLK2P (Supplementary Table 4).
Variant rs146336907:C > T was not observed in 1KG or
UK10K (Supplementary Table 4).
DNA methylation in associated genes
To support our associations observed from single variants
and gene-based association test, we performed DNA
methylation analyses of CpG located ± 20 kb from the
associated genes (Supplementary Table 5) in whole blood
(167 samples) or isolated eosinophils. The methylation
levels of 49 CpG sites of NRP2 were tested for association
with serum IgE levels and nine CpGs with p < 0.05 (one
with p < 2.8e–4) were detected, which is larger than
expected (4.8 CpG) in isolated eosinophils (Supplementary
Table 5). No associations were found between CXCR6/
FYCO1, MRPL44 and SHMT1/SMCR8 methylation levels
and asthma nor CCDC26/CLK2P with FEV1/FVC (Sup-
plementary Table 5).
Discussion
In our study, we characterized the variants distribution of
rare and low-frequency variants in the SLSJ population, the
enrichment of deleterious variants and their impacts on
asthma and allergy-related traits. In terms of the variants
distribution, overall observations in FINN were consistent
with the published ﬁndings of another Finnish population
genetic study [14]; higher proportions of population-speciﬁc
rare and low-frequency variants and fewer rare variants as
compared with non-founder populations. Unlike the pub-
lished ﬁndings [14], no differences in proportions were
detected in FINN when variants were stratiﬁed by function;
it is likely due to small sample sizes. Similar to the ﬁndings
of another French-Canadian population genetic study [13], a
higher proportion of low-frequency variants was observed
compared with non-founder populations. However, contrary
to the same study [13], we observed a smaller proportion of
rare population-speciﬁc variants in SLSJ and no difference
in the proportion of low-frequency nonsynonymous variants
as compared with non-founder populations; the latter likely
due to a small sample size. However, a larger proportion of
population-speciﬁc variants reached higher frequencies in
the founder populations, reﬂecting the genetic drift asso-
ciated with them. Our results are consistent with previous
studies in terms of enrichments of deleterious variants in
founder populations, especially in the low-frequency
Table 3 Results of single low-frequency SNV association study with asthma-related traits (p < 1e–5)
Trait rsID Gene Alleles MAF p-Valuea Effect (SE)
Serum IgE levels chr2:g.206562250 T > C; rs849558 NRP2; intron T/C 0.019 4.79e–6 –1.243 (0.270)
Eosinophils percentage chr3:g.45989502 C > T; rs1386931 CXCR6; 3ʹ-UTR and FYCO1; intron C/T 0.043 1.77e–6 1.534 (0.319)
MAF minor allele frequency, SE standard error, IgE immunoglobulin E, UTR untranslated region, NRP2 neuropilin 2, CXCR6 C-X-C motif
chemokine receptor 6
a p-Value in bold is those reaching the signiﬁcance threshold of 3.3e–6
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spectrum of variants [13, 14]. Various factors may con-
tribute to the differences in the ﬁndings between our study
and others. The strength of our assessment resides in
comparing two founder and three non-founder populations
with identical experimental procedures and samples paired
based on mean coverage.
By investigating low-frequency variants in SLSJ, new
genes have been identiﬁed for their associations with
asthma or allergy-related traits. Using variant-based ana-
lyses, FYCO1, CXCR6 and NRP2 shed new light to
mechanisms inﬂuencing allergy. Variant rs1386931:C > T is
located in an intron of FYCO1 and 3ʹ-UTR of the CXCR6.
FYCO1 encodes for a protein that plays a role in the
transport of autophagic vesicles [43], and autophagy and its
genes were associated with asthma [44–48]. CXCR6
encodes for a chemokine receptor expressed on the surface
of multiple immune cell types and was associated with
asthma and Th2 inﬂammation in the lung [49, 50]. Variant
rs849558:T > C is located in an intron of NRP2. It is a
transmembrane receptor implicated in multiple processes,
including antigen presentation, phagocytosis and cell–cell
interaction [51]. This gene was also associated in the gene-
based test; being led by the same associated SNV and was
supported by DNA methylation association. Given that
Fig. 2 Manhattan and qqplot plot for low-frequency single-variant
association test for a serum IgE levels (lambda= 1.01, with associated
qqplot (b)); and c eosinophil percentage (lambda= 1.08, with
associated qqplot (d)). Signiﬁcance cut-off are shown in blue
(p < 1e–5) and red (Bonferroni, p < 3.3e–6)
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Table 4 Genes signiﬁcantly associated with asthma and allergy-related traits (p < 3.4e–6)
Trait Gene n SNPs n passinga Fraction with rare p-Value SKAT/CMCb Lead SNVsc
Eosinophils percentage MRPL44 8 4 0.026 2.97e–6/5.74e–5 chr2:g.224835223 T > G; rs76568361
Serum IgE levels NRP2 4 2 0.001 3.16e–6/0.8237 chr2:g.206562250 T > C; rs849558
SKAT sequence kernel association test, CMC combined multivariate and collapsing test, SNV single-nucleotide variations, IgE immunoglobulin E,
NRP2 neuropilin 2, MRPL44 mitochondrial ribosomal protein L44
a Number of variants passing threshold (MAF < 0.05)
b p-Values in bold are those reaching the signiﬁcance threshold of 3.4e–6
c Test were ran again removing one variant at a time, lead SNV correspond to the one for which the entire association rely on
Fig. 3 Manhattan plot and qqplot for SKAT test with a serum IgE
levels (lambda= 1.05, with associated qqplot (b)) and c eosinophil
percentage (lambda= 1.13, with associated qqplot (d)). SKAT
Sequence Kernel Association Test. Signiﬁcance cut-off are shown in
blue (p < 1e–5) and red (Bonferroni, p < 3.4e–6)
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serum IgE levels and eosinophil percentage are associated
with various allergic diseases, we tested variants rs849558:
T > C and rs1386931:C > T for associations with additional
disease phenotypes: asthma, atopy, allergic asthma, rhinitis
and atopic dermatitis (Supplementary Table 6). NRP2 var-
iant rs849558:T > C was marginally associated with atopy
and allergic asthma. CXCR6/FYCO1 variant rs1386931:C >
T was associated with atopic dermatitis. These ﬁndings
point at plausible disease mechanisms of allergic diseases.
Using a gene-based approach, there are now suggestive
roles of MRPL44 and SERPINE2 in mediating eosinophil
percentage. MRPL44 is implicated in protein synthesis in
mitochondria and that mitochondria play an important role
in eosinophil apoptosis and survival [52]. Moreover, the
lead SNV for MRPL44 is located in the promoter region of
the SERPINE2 gene, for which the association was sug-
gestive (p= 1.47e–5). SERPINE2 is a serine protease
inhibitor and is a known susceptibility gene for chronic
obstructive pulmonary disease [53], emphysema [54] and
asthma [55]. Our ﬁndings suggest a novel role of SER-
PINE2 in eosinophils.
Conclusion
In this study, we showed that founder populations are
enriched with deleterious low-frequency variants and that
they present population-speciﬁc variants with higher fre-
quencies. By examining rare and low-frequency variants for
their associations with asthma and allergy-related traits in a
founder population, we identiﬁed new genes worthy of
further study. One of the lead SNV in the gene-based test
was speciﬁc to the SLSJ population highlighting the
importance of using sequencing data in founder population
to identify new genes associated with complex traits. Other
SNV also presented marginally higher frequency compared
with the European populations. We also demonstrate the
importance of addressing the non-coding regions of the
genome by using sequencing studies, as three of the variants
identiﬁed were non-coding and located in immune reg-
ulatory regions. Overall, we showed the usefulness of using
a well-described founder population and the importance of
assessing non-coding regions to better decipher the genetic
basis of complex traits.
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